Index of artpub/2024/311089/

González-Calle, Verónica
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma : results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
2024
https://ddd.uab.cat/record/311089